MétaCan
Menu
Back to cohort
Record W4210650500 · doi:10.1001/jamaneurol.2021.5216

Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

2022· article· en· W4210650500 on OpenAlex

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.
fundA Canadian funder is recorded on the work.

Bibliographic record

VenueJAMA Neurology · 2022
Typearticle
Languageen
FieldMedicine
TopicDementia and Cognitive Impairment Research
Canadian institutionsMontreal Neurological Institute and HospitalAlzheimer Society of CanadaMcGill UniversityDouglas Mental Health University Institute
FundersCliniques Universitaires Saint-LucNational Institute on AgingFaculty of Medicine and Health, University of SydneyHealthy Aging Research CenterSahlgrenska AkademinWydział Lekarski, Uniwersytet Jagielloński Collegium MedicumUniversity of California, San FranciscoSamsungGenentechMedizinische Fakultät der Albert-Ludwigs-Universität FreiburgUniversité de ParisAmsterdam NeuroscienceSorbonne UniversitéInstituto de Investigación Marqués de ValdecillaUK Dementia Research InstituteCentro de Investigación Biomédica en Red sobre Enfermedades NeurodegenerativasShionogiAkershus UniversitetssykehusAlzheimer NederlandRégion NormandieNational Institute of Neurological Disorders and StrokeUniversitatea de Medicină şi Farmacie "Carol Davila" BucureştiInstitut National de la Santé et de la Recherche MédicaleH. Lundbeck A/SUniversité Paris-SaclayUniversity of Texas at DallasServierInstitut de Neurosciences des SystèmesSiemens HealthineersNovo NordiskUniversità degli Studi di BresciaUppsala UniversitetInstituto de Salud Carlos IIIUniversidad de CantabriaFondation pour la Recherche sur AlzheimerRadboud Universitair Medisch CentrumGöteborgs UniversitetUniversität zu KölnIrving Medical Center, Columbia UniversityAristotle University of ThessalonikiChang Gung UniversitySahlgrenska UniversitetssjukhusetDeutsches Zentrum für Neurodegenerative ErkrankungenNational and Kapodistrian University of AthensEisaiLeids Universitair Medisch CentrumBrigham and Women's HospitalInstytut Medycyny Doswiadczalnej i Klinicznej im. M. Mossakowskiego, Polskiej Akademii NaukAlbert-Ludwigs-Universität FreiburgChang Gung Medical FoundationRheinische Friedrich-Wilhelms-Universität BonnVrije Universiteit BrusselLinköpings UniversitetUniversiteit AntwerpenSeoul National University HospitalUniversità degli Studi di GenovaKuopion Yliopistollinen SairaalaAmsterdam University Medical CentersKarolinska InstitutetUniversidade de CoimbraÖrebro UniversitetTechnische Universität MünchenNederlandse Organisatie voor Wetenschappelijk OnderzoekImperial College LondonKing's College LondonGentofte HospitalLawrence Berkeley National LaboratoryEuropean Regional Development FundSeoul National UniversityKU LeuvenUniversity of PittsburghUniversiteit MaastrichtUniversité de GenèveVrije Universiteit AmsterdamEli Lilly and CompanyRadboud UniversiteitUniversität HeidelbergUniversità di BolognaAlnylam PharmaceuticalsProthenaEuropean CommissionBrown UniversityNewcastle UniversityLunds UniversitetInstitut de Recherches ServierUniversity of SydneyUniversité de LausanneMassachusetts General HospitalUniwersytet Jagielloński Collegium MedicumUniversity College LondonAvid RadiopharmaceuticalsCentre National de la Recherche ScientifiqueCarl von Ossietzky Universität OldenburgUniversitätsmedizin GöttingenLui Che Woo Institute of Innovative MedicineUniversité de Caen NormandieTurun YliopistoAssistance publique-Hôpitaux de ParisBiogenRigshospitaletCelgeneSungkyunkwan UniversityFaculty of Medicine, McGill UniversityUniverzita Karlova v PrazeMcGill UniversityEmory UniversityCouncil of Scientific and Industrial Research, IndiaNorges Teknisk-Naturvitenskapelige UniversitetAlzheimer's AssociationThomas Jefferson UniversityWeill Cornell Medical CollegeUniversity of PennsylvaniaAarhus UniversitetZonMwPostgraduate Institute of Medical Education and Research, ChandigarhPerelman School of Medicine, University of PennsylvaniaMcLean HospitalUniversitätsklinikum KölnNational Institutes of HealthChinese University of Hong KongItä-Suomen Yliopisto
KeywordsDementiaBiomarkerCognitionAbnormalityMedicineCognitive declineDiseaseAlzheimer's diseaseCohortInternal medicineCognitive testPsychologyOncologyPathologyPsychiatry

Abstract

fetched live from OpenAlex

IMPORTANCE: One characteristic histopathological event in Alzheimer disease (AD) is cerebral amyloid aggregation, which can be detected by biomarkers in cerebrospinal fluid (CSF) and on positron emission tomography (PET) scans. Prevalence estimates of amyloid pathology are important for health care planning and clinical trial design. OBJECTIVE: To estimate the prevalence of amyloid abnormality in persons with normal cognition, subjective cognitive decline, mild cognitive impairment, or clinical AD dementia and to examine the potential implications of cutoff methods, biomarker modality (CSF or PET), age, sex, APOE genotype, educational level, geographical region, and dementia severity for these estimates. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional, individual-participant pooled study included participants from 85 Amyloid Biomarker Study cohorts. Data collection was performed from January 1, 2013, to December 31, 2020. Participants had normal cognition, subjective cognitive decline, mild cognitive impairment, or clinical AD dementia. Normal cognition and subjective cognitive decline were defined by normal scores on cognitive tests, with the presence of cognitive complaints defining subjective cognitive decline. Mild cognitive impairment and clinical AD dementia were diagnosed according to published criteria. EXPOSURES: Alzheimer disease biomarkers detected on PET or in CSF. MAIN OUTCOMES AND MEASURES: Amyloid measurements were dichotomized as normal or abnormal using cohort-provided cutoffs for CSF or PET or by visual reading for PET. Adjusted data-driven cutoffs for abnormal amyloid were calculated using gaussian mixture modeling. Prevalence of amyloid abnormality was estimated according to age, sex, cognitive status, biomarker modality, APOE carrier status, educational level, geographical location, and dementia severity using generalized estimating equations. RESULTS: Among the 19 097 participants (mean [SD] age, 69.1 [9.8] years; 10 148 women [53.1%]) included, 10 139 (53.1%) underwent an amyloid PET scan and 8958 (46.9%) had an amyloid CSF measurement. Using cohort-provided cutoffs, amyloid abnormality prevalences were similar to 2015 estimates for individuals without dementia and were similar across PET- and CSF-based estimates (24%; 95% CI, 21%-28%) in participants with normal cognition, 27% (95% CI, 21%-33%) in participants with subjective cognitive decline, and 51% (95% CI, 46%-56%) in participants with mild cognitive impairment, whereas for clinical AD dementia the estimates were higher for PET than CSF (87% vs 79%; mean difference, 8%; 95% CI, 0%-16%; P = .04). Gaussian mixture modeling-based cutoffs for amyloid measures on PET scans were similar to cohort-provided cutoffs and were not adjusted. Adjusted CSF cutoffs resulted in a 10% higher amyloid abnormality prevalence than PET-based estimates in persons with normal cognition (mean difference, 9%; 95% CI, 3%-15%; P = .004), subjective cognitive decline (9%; 95% CI, 3%-15%; P = .005), and mild cognitive impairment (10%; 95% CI, 3%-17%; P = .004), whereas the estimates were comparable in persons with clinical AD dementia (mean difference, 4%; 95% CI, -2% to 9%; P = .18). CONCLUSIONS AND RELEVANCE: This study found that CSF-based estimates using adjusted data-driven cutoffs were up to 10% higher than PET-based estimates in people without dementia, whereas the results were similar among people with dementia. This finding suggests that preclinical and prodromal AD may be more prevalent than previously estimated, which has important implications for clinical trial recruitment strategies and health care planning policies.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.017
Threshold uncertainty score0.999

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.040
GPT teacher head0.386
Teacher spread0.346 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it